MedTrace Logo

Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease

NCT02500784 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-09-16

No results posted yet for this study

Summary

The purpose of this study is to test the effects of long-term therapeutic doses of formoterol, on a) cerebrospinal fluid (CSF) tau levels, and Amyloid Beta protein 40/42 levels in the CSF, and b) cognitive function in people with mild to moderate Alzheimer' Disease (AD).

Conditions

Interventions

DRUG

Formoterol A

20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.

OTHER

Formoterol B (placebo)

2mL, BID inhaler for 12 months

Sponsors & Collaborators

  • Alzheimer's Association

    collaborator OTHER

  • Mylan Inc.

    collaborator INDUSTRY

  • Palo Alto Veterans Institute for Research

    lead OTHER

Principal Investigators

  • Ahmad Salehi, M.D.,Ph.D. · Stanford Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2025-04-30
Completion
2025-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02500784 on ClinicalTrials.gov